In April 2005,Canadian authorities approved the marketing of Sativex, a mouth spray for multiple sclerosis to alleviate pain.Sativex contains tetrahydrocannabinol together with Cannabidiol. Initial research is showing that CBD has an effect in reducing schizophrenic symptoms in patients. Futher research has verified these results. Leweke et al.,(2009)perfomed a double bind.4 week. explorative study controlled clinical trial,to compare the effects of purified cannabidiol and the atypical antipsychotic amisulpride on improving the symptoms of schizophrenia in 42 patients with acute schizophrenia. 'Both treatments were associated with a significant decrease of psychotic sympoms after 2 and 4 weeks as assessed by BPRS and PANSS. However, there was no statistical difference between both treatment groups. In contrast, cannabidiol induced significantly less side effects(EPS,increase in prolactin, weight gain) when compared to amisulpride'. The authors conclude cannabidiol revealed substantial antipsychotic properties in acute paranoid schizophirenia (Leweke et al.,2009).This led the authors to suggest the endocannabinoid system plays an adaptive role in the development of paranoid schizophirenia and that this research provides evidence that this mechanism may be a valuable target for 'antipsychotic treament strategies'